Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.37 |
| ▸ | NAMPT | P43490 | 4/20 | 0.36 |
| ▸ | OXTR | P30559 | 1/20 | 0.35 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.35 |
| ▸ | WNT1 | P04628 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | KRAS | P01116 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30553342 | 1.00 | GPR119 (0.37) | GPR119NAMPTOXTRAVPR1AWNT1 | |
| SCHEMBL30700866 | 0.82 | GPR119 (0.44) | GPR119 | |
| SCHEMBL31308773 | 0.82 | GPR119 (0.44) | GPR119 | |
| SCHEMBL31365784 | 0.81 | GPR119 (0.37) | GPR119NAMPTOXTRAVPR1AWNT1 | |
| SCHEMBL31365771 | 0.81 | GPR119 (0.37) | GPR119NAMPTOXTRAVPR1AWNT1 | |
| SCHEMBL30408922 | 0.80 | GPR119 (0.40) | GPR119OXTRAVPR1AKRASRORC | |
| SCHEMBL30553347 | 0.80 | GPR119 (0.43) | GPR119 | |
| SCHEMBL25326568 | 0.80 | GPR119 (0.43) | GPR119 | |
| SCHEMBL25325390 | 0.80 | GPR119 (0.38) | GPR119NAMPTOXTRAVPR1AWNT1 | |
| SCHEMBL30012131 | 0.80 | GPR119 (0.38) | GPR119NAMPTOXTRAVPR1AWNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | disclosed |
| CN-119654326-A | Novel heterocyclic compounds | 豪夫迈·罗氏有限公司 | 2025-03-18 | — | — | CN | disclosed |
| WO-2024033277-A1 | NEW HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2024-02-15 | — | — | WO | disclosed |
| WO-2023144160-A1 | NEW HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | OPRM1, CYP1A1, CYP3A4 | GPR119 1935/4885NAMPT 965/4885OXTR 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.